Gilead Sciences, Inc. (GILD) — closed signal from January 7, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 7, 2026 — +11.8% at the close.
Predicted vs. what happened
What happened
Reached its target in 19 days.
The thesis — published January 7, 2026
Gilead is a relatively steady healthcare pick to help protect a portfolio if markets get rough. The company announced a research deal with OncoNano about a drug-delivery method that could bring future payments. Investors are also watching its cancer drug programs such as TIGIT. The plan here is to buy on small price drops in a big, liquid company rather than chase fast gains.
Primary drivers
- New collaboration could add future drug possibilities
- Cancer programs may draw investor attention to the stock
- Seen as more stable if investors get nervous
- Buying dips suits a steady, cautious approach
How it played out
GILD: target reached in 19 days
Lyra published GILD at $124.20 on 2026-01-07 for a short-term window ending 2026-04-07. The thesis expected 10% growth and a target of $136.62. It pointed to a new OncoNano collaboration, cancer programs such as TIGIT, the stock's steadier healthcare profile if markets got rough, and a plan to buy small price drops rather than chase fast gains.
Inside the window, GILD rose past the target. It peaked at $157.29 on 2026-02-11, with a 26.6% peak gain, and reached the target in 19 days. It ended the window at $138.80, still above the target. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.